These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 18271062

  • 21. Improvement of peripheral nervous system manifestations of B-cell non-Hodgkin's lymphoma after rituximab therapy.
    Briani C, Zambello R, Cavallaro T, Ferrari S, Lucchetta M, Pollanz S, Grisold W.
    J Peripher Nerv Syst; 2009 Jun; 14(2):146-8. PubMed ID: 19691537
    [No Abstract] [Full Text] [Related]

  • 22. B-cell lymphoma in a girl with ataxia teleangiectasia (A-T) treated with rituximab monotherapy.
    Kropshofer G, Wehl G, Klein-Franke A, Högler W, Meister B.
    Pediatr Blood Cancer; 2006 Apr; 46(4):528-9. PubMed ID: 16123984
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Splenic marginal zone lymphoma: transformation to diffuse large B-cell lymphoma with isolated cerebral manifestation.
    Thoennissen NH, Keyvani K, Voelker HU, Bremer J, Krug U, Müller-Tidow C, Koch P, Müller-Hermelink HK, Berdel WE.
    J Clin Oncol; 2008 Sep 20; 26(27):4509-11. PubMed ID: 18802164
    [No Abstract] [Full Text] [Related]

  • 26. Rituximab: mechanisms and applications.
    Johnson PW, Glennie MJ.
    Br J Cancer; 2001 Nov 30; 85(11):1619-23. PubMed ID: 11742477
    [No Abstract] [Full Text] [Related]

  • 27. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone.
    Tsimberidou AM, Catovsky D, Schlette E, O'Brien S, Wierda WG, Kantarjian H, Garcia-Manero G, Wen S, Do KA, Lerner S, Keating MJ.
    Cancer; 2006 Jul 01; 107(1):125-35. PubMed ID: 16700034
    [Abstract] [Full Text] [Related]

  • 28. Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance.
    Kalpadakis C, Pangalis GA, Sachanas S, Tsirkinidis P, Kontopidou FN, Moschogiannis M, Yiakoumis X, Koulieris E, Dimopoulou MN, Kokkoris SI, Kyrtsonis MC, Siakantaris MP, Tsourouflis G, Korkolopoulou P, Rontogianni D, Tsaftaridis P, Plata E, Papadaki HA, Panagiotidis P, Angelopoulou MK, Vassilakopoulos TP.
    Blood; 2018 Aug 09; 132(6):666-670. PubMed ID: 29914978
    [No Abstract] [Full Text] [Related]

  • 29. Optimizing rituximab in B-cell lymphoma.
    Horning SJ.
    J Clin Oncol; 2005 Feb 20; 23(6):1056-8. PubMed ID: 15657408
    [No Abstract] [Full Text] [Related]

  • 30. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.
    Kasteng F, Erlanson M, Hagberg H, Kimby E, Relander T, Lundkvist J.
    Acta Oncol; 2008 Feb 20; 47(6):1029-36. PubMed ID: 18607857
    [Abstract] [Full Text] [Related]

  • 31. Rituximab in diffuse large B-cell lymphoma.
    Coiffier B.
    Clin Adv Hematol Oncol; 2004 Mar 20; 2(3):156-7. PubMed ID: 16166943
    [No Abstract] [Full Text] [Related]

  • 32. Effective therapeutic use of rituximab in refractory Wegener's granulomatosis.
    Ferraro AJ, Day CJ, Drayson MT, Savage CO.
    Nephrol Dial Transplant; 2005 Mar 20; 20(3):622-5. PubMed ID: 15735243
    [No Abstract] [Full Text] [Related]

  • 33. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy.
    Kalpadakis C, Pangalis GA, Angelopoulou MK, Sachanas S, Kontopidou FN, Yiakoumis X, Kokoris SI, Dimitriadou EM, Dimopoulou MN, Moschogiannis M, Korkolopoulou P, Kyrtsonis MC, Siakantaris MP, Papadaki T, Tsaftaridis P, Plata E, Papadaki HE, Vassilakopoulos TP.
    Oncologist; 2013 Mar 20; 18(2):190-7. PubMed ID: 23345547
    [Abstract] [Full Text] [Related]

  • 34. Rituximab for intraocular lymphoma.
    Itty S, Pulido JS.
    Retina; 2009 Feb 20; 29(2):129-32. PubMed ID: 19202422
    [No Abstract] [Full Text] [Related]

  • 35. Rituximab as first line treatment for MALT lymphoma of extraocular muscles.
    Benetatos L, Alymara V, Asproudis I, Bourantas KL.
    Ann Hematol; 2006 Sep 20; 85(9):625-6. PubMed ID: 16691396
    [No Abstract] [Full Text] [Related]

  • 36. The role of splenectomy in splenic marginal zone B-cell lymphoma.
    Marti GE.
    Clin Lymphoma; 2002 Jun 20; 3(1):48. PubMed ID: 12141955
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Improvement of recurrent urticaria in a patient with Schnitzler syndrome associated with B-cell lymphoma with combination rituximab and radiotherapy.
    Murota H, Shoda Y, Ishibashi T, Sugahara H, Matsumura I, Katayama I.
    J Am Acad Dermatol; 2009 Dec 20; 61(6):1070-5. PubMed ID: 19632739
    [Abstract] [Full Text] [Related]

  • 39. Rituximab alone was effective for the treatment of a diffuse large B-cell lymphoma associated with hemophagocytic syndrome.
    Sano T, Sakai H, Takimoto K, Ohno H.
    Int J Clin Oncol; 2007 Feb 20; 12(1):59-62. PubMed ID: 17380444
    [Abstract] [Full Text] [Related]

  • 40. Renal intravascular large B-cell lymphoma with early diagnosis by renal biopsy: a case report and review of the literature.
    Niitsu N, Okamura D, Takahashi N, Tanae K, Hagiwara Y, Kayano H, Bessho M.
    Leuk Res; 2009 May 20; 33(5):728-30. PubMed ID: 19036442
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.